For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Licensing revenue | 0 | 850 | ||
| Research and development | 55,969 | 42,342 | ||
| General and administrative | 16,870 | 15,133 | ||
| Total operating expenses | 72,839 | 57,475 | ||
| Loss from operations | -72,839 | -56,625 | ||
| Interest income | 6,350 | 7,250 | ||
| Net loss | -66,489 | -49,375 | ||
| Unrealized gain on marketable securities | 70 | 173 | ||
| Comprehensive loss | -66,419 | -49,202 | ||
| Basic EPS | -0.42 | -0.36 | ||
| Basic Average Shares | 157,695,000 | 137,384,000 | ||
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)